EBOS GROUP LIMITED (EBO)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

EBO

EBO - EBOS GROUP LIMITED

FNArena Sector : Healthcare services
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 2.84
Index: ASX300 | ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$18.04

24 Mar
2026

-0.300

OPEN

$18.52

-1.64%

HIGH

$18.52

136,327

LOW

$17.97

TARGET
$27.69 53.5% upside
Franking for last dividend paid out: 95%
OTHER COMPANIES IN THE SAME SECTOR
ACL . ALC . BMT . DOC . HLS . IDX . M7T . MPL . MVF . NHF . RHC . SHL .
FNARENA'S MARKET CONSENSUS FORECASTS
EBO: 1
Title FY24
Actual		 FY25
Actual		 FY26
Forecast		 FY27
Forecast
EPS (cps) xxx 109.7 128.4 xxx
DPS (cps) xxx 112.9 104.8 xxx
EPS Growth xxx - 22.4% 17.0% xxx
DPS Growth xxx N/A - 7.2% xxx
PE Ratio xxx N/A 14.6 xxx
Dividend Yield xxx N/A 5.6% xxx
Div Pay Ratio(%) xxx 102.9% 81.6% xxx

Dividend yield today if purchased 3 years ago: 2.67%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 6.02

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 04/09 - ex-div 49.19c (franking 95%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx109.7
DPS All xxxxxxxxxxxxxxx112.9
Sales/Revenue xxxxxxxxxxxxxxx12,266.9 M
Book Value Per Share xxxxxxxxxxxxxxx1,348.0
Net Operating Cash Flow xxxxxxxxxxxxxxx418.5 M
Net Profit Margin xxxxxxxxxxxxxxx1.75 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx8.29 %
Return on Invested Capital xxxxxxxxxxxxxxx5.70 %
Return on Assets xxxxxxxxxxxxxxx3.07 %
Return on Equity xxxxxxxxxxxxxxx8.29 %
Return on Total Capital xxxxxxxxxxxxxxx10.08 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx156.3 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx82 M
Long Term Debt xxxxxxxxxxxxxxx1,540 M
Total Debt xxxxxxxxxxxxxxx1,622 M
Goodwill - Gross xxxxxxxxxxxxxxx2,245 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx184 M
Price To Book Value xxxxxxxxxxxxxxx2.64

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx146.0 M
Capex % of Sales xxxxxxxxxxxxxxx1.19 %
Cost of Goods Sold xxxxxxxxxxxxxxx11,346 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx497 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx95 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

5
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Ord Minnett

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

26/02/2026

1

Outperform

-

-

Ebos Group delivered first half underlying EBITDA that was lower than Macquarie anticipated while full year guidance is unchanged. The company remains confident of the skew to the second half.

In terms of composition, animal care beat estimates, offsetting a miss in healthcare. The broker suggests the catalysts are skewed to the upside and long-term volume data bears out the defensive nature of animal/healthcare segments.

The company will hold its Sydney investor briefing on April 30. Target is reduced to NZ$39.00 from NZ$39.78. Outperrform rating retained.

FORECAST
Macquarie forecasts a full year FY26 dividend of 100.20 cents and EPS of 128.10 cents.
Macquarie forecasts a full year FY27 dividend of 107.20 cents and EPS of 145.80 cents.

Citi

xx/xx/xxxx

1

xxxxxxx xx xxx xxxx xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

UBS

xx/xx/xxxx

1

xxx

-

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Jarden

23/03/2026

2

Overweight

-

-

Ebos Group has underperformed over the past year, with Jarden highlighting a -38% total shareholder loss against the NZX50’s 9% gain amid earnings resets and contract loss impacts.

While the 1H26 result showed early progress in the operating reset, the analysts explain higher leasing and depreciation from distribution centre upgrades drove further earnings downgrades.

Growth prospects are seen as being supported by pharmaceutical demand trends, with PBS expansion and specialty medicines supporting Community Pharmacy operations.

In the event of strong execution, Jarden sees stabilisation in PBS share near 29%. An Overweight rating and target of NZ$34 are maintained.

FORECAST
Jarden forecasts a full year FY26 dividend of 105.00 cents and EPS of 126.00 cents.
Jarden forecasts a full year FY27 dividend of 106.00 cents and EPS of 129.10 cents.
Access Extra Coverage Research History >

EBO STOCK CHART

FNArena News on EBO

1
Australian Broker Call *Extra* Edition – Mar 23, 2026

Mar 23 2026 - Daily Market Reports
2
Next Week At A Glance – 23-27 Mar 2026

Mar 20 2026 - Weekly Reports
3
Australian Broker Call *Extra* Edition – Mar 05, 2026

Mar 05 2026 - Daily Market Reports
4
Weekly Ratings, Targets, Forecast Changes – 27-02-26

Mar 02 2026 - Weekly Reports
5
FNArena Corporate Results Monitor – 26-02-2026

Feb 26 2026 - Australia

Latest Healthcare services News

1
Better Times Ahead For Sonic Healthcare?

Jun 20 2025 - Australia
2
The Significance Of Cosmetique’s ASX Listing

Feb 26 2025 - Small Caps
3
Building The No 3 Diagnostic Imaging Player

Jun 19 2024 - Small Caps
4
Capitol Health’s Higher Margin Outlook

Mar 13 2024 - Small Caps
5
Treasure Chest: Ramsay Health Care

Oct 26 2023 - Treasure Chest
6
Timing Seems Right For Alcidion Group

Jun 21 2023 - Small Caps
7
No Enthusiasm To Combine ACL & Healius

Mar 21 2023 - Australia
8
Dr Boreham’s Crucible: Alcidion

Dec 13 2022 - Small Caps
9
No Straight Covid-Relief For Ramsay Health Care

Nov 15 2022 - Australia
10
Dr Boreham’s Crucible: Mach7 Technologies

Nov 14 2022 - Small Caps